Circulating Tumor Cells Following First Chemotherapy Cycle: An Early and Strong Predictor of Outcome in Patients With Metastatic Breast Cancer
Fecha
19/07/2013Autor
Estado
info:eu-repo/semantics/publishedVersionMetadatos
Mostrar el registro completo del ítemResumen
. Weinvestigated the prognostic significance of circulating tumor
cells (CTCs) determined immediately before the second cycle of
chemotherapy in patients with metastatic breast cancer (MBC).
The CTC counts were taken at baseline, before the first cycle of
chemotherapy (CTC-0) and on day 21 before commencing the
second cycle of chemotherapy (CTC-21) in consecutive MBC patients.
The study s primary objectives were to analyze relationships
between CTC-21 count and overall survival (OS). Based on
the current literature, the CTC measurements were dichotomizedas0
4versus 5CTCs.Of117patients recruited,99were
evaluable. Patients with 0 4 CTCs on day 21 had a significantly
better OS than those with 5 CTCs (median OS: 38.5 months vs.
8.7months).Theyalsohadasignificantly better progression-free
survival (PFS; median: 9.4 months vs. 3.0 months) and clinical
benefit rate (77% vs. 44%). The OS of patients whose baseline
CTCs were 5 but dropped to 5 on day 21 was apparently similar
to those who had 5 CTCs at baseline. In a Cox regression
analysis, CTC-21 was the only independent variable significantly
predicting OS and PFS. Our data indicate that CTCs determined
immediatelybeforethesecondcycle ofchemotherapyisanearly
andstrong predictor of treatmentoutcomeinMBCpatients. The
Oncologist2013;18:000 000
Circulating Tumor Cells Following First Chemotherapy Cycle: An Early and Strong Predictor of Outcome in Patients With Metastatic Breast Cancer
Tipo de Actividad
Artículos en revistasISSN
1083-7159Palabras Clave
.Circulating tumor cells Outcome prediction Metastatic breast cancer